Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Graphic showing light bulbs with numbers on

Committing time to making meaningful connections – top 5 tips

Read the second blog of the series looking at key barriers to effective patient engagement in pharma

Cuttsy + Cuttsy

News:

Senior Analytics Specialist joins Research Partnership

Inizio

Sanofi reception

Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis

New long-term data presented at ECTRIMS 2021 reinforces promising safety and efficacy profile

Biogen Idec building

Data shows patients treated with Biogen’s MS therapies mount an effective antibody response to COVID-19 vaccination

New MS PATHS data was presented at ECTRIMS 2021

- PMLiVE

Healthcare creatives need to be more like Bryson

By James Mayfield

Digital technologies: Pharma’s answer to achieving net zero emissions?

As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent...

Impetus Digital

- PMLiVE

Future focus: 3 tools for launching fast in the face of uncertainty

Dan Twibell, Head of Commercial Strategy, Consulting at Fishawack Health, reveals 3 fundamental tools for lean biotechs approaching a rapid launch. He gives his advice on how to manage resources...

Avalere Health

- PMLiVE

Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir

If authorised, molnupiravir could be the first oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in at risk adults

- PMLiVE

bluebird bio provides update on 2seventy bio spin-off

The company has also announced the appointment of two new board members, Najoh Tita-Reid and Sarah Glickman

- PMLiVE

Lupus Awareness Month

In this second October’s blog, we will be looking into Lupus in clinical trials: its symptoms, complications, treatments, incidence and focus on diversity.

Innovative Trials

- PMLiVE

How should healthcare harness creativity?

By Rob Gale

- PMLiVE

Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death

The antibody is the only long-acting combination shown to both prevent and treat COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links